The Expanding Role of CAR T Cells in Lymphoma and Leukemia
Dr. Miklos on Alternative Options to KTE-X19 in MCL, While Awaiting FDA Decision
David Miklos, MD, discusses alternative options to the investigational CAR T-cell therapy KTE-X19 for patients with relapsed/refractory mantle cell lymphoma, while awaiting a regulatory decision from the FDA.
Dr. Miklos on Anticipated Sequencing Challenges With KTE-X19 in MCL
David Miklos, MD, discusses anticipated sequencing challenges with the investigational CAR T-cell therapy KTE-X19 in mantle cell lymphoma.
2 Commerce Drive Cranbury, NJ 08512